A recent project involving Sensidose and Recipharm has produced a novel microtablet dosage form that will benefit specific patients suffering from Parkinson’s disease. The two companies reveal how such collaborations can create new products from existing active ingredients.
The diminished number of new chemical entities being introduced onto the market in recent years is a significant challenge for the pharmaceutical industry and may jeopardise the steady stream of new valuable medicines that the healthcare sector and consumers have got used to. There are multiple factors that, it might be argued, have contributed to this shortfall, including the fact that the easy, low-hanging fruit have already been picked and supplied; the expense and inefficiencies of r&d organisations in pharmaceutical companies; and the increasing regulatory hurdles.
As a consequence, it has become very attractive to develop new pharmaceutical products based on existing active ingredients. This approach means that development costs and the risks of failure are much lower, and substantial therapeutic benefits can be achieved.
Presently, there are many small companies working with innovative ideas in this area. But to turn these ideas into actual developed products requires effective collaboration between these small innovative companies and Contract Development and Manufacturing Organisations (CDMOs).
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.